{"url_path":"/sec/eltp/10-k/2026/item-3","section_key":"item-3","section_title":"Item 3 LEGAL PROCEEDINGS**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1053369/0001493152-26-031070-index.html","accession_number":"0001493152-26-031070","cik":"0001053369","ticker":"ELTP","issuer_name":"ELITE PHARMACEUTICALS INC /NV/","edgar_url":"https://www.sec.gov/Archives/edgar/data/1053369/0001493152-26-031070-index.html","primary_entity_key":"0001053369","primary_entity_name":"ELITE PHARMACEUTICALS INC /NV/"},"word_count":260,"has_tables":true,"body_markdown":"**ITEM\n3. LEGAL PROCEEDINGS**\n\n \n\nOn\nAugust 17, 2023, Elite filed a Paragraph IV certification with its ANDA to generic Oxycontin and after Elite got acceptance of the ANDA\nby the FDA on September 19, 2023, Elite sent the patentee and NDA holder a Notice Letter as required under the Hatch-Waxman Act. On November\n14, 2023, a patent infringement suit was filed in the District Court of New Jersey by Purdue Pharma. The parties agreed to a stipulated dismissal of the case and the judge signed the order dismissing the case on June\n12, 2026.\n\n \n\nElite’s\nlaunch of a generic Oxycontin will depend on approval by the FDA and the outcome of various litigation involving Purdue or the expiry\nof the patents listed on the Orange Book.\n\n \n\nIn\nthe ordinary course of business, we may be subject to litigation from time to time. There is no current, pending or, to our knowledge,\nthreatened litigation or administrative action to which we are a party or of which our property is the subject (including litigation\nor actions involving our officers, directors, affiliates, or other key personnel, or holders of record or beneficially of more than 5%\nof any class of our voting securities, or any associate of any such party) which in our opinion has, or is expected to have, a material\nadverse effect upon our business, prospects financial condition or operations. A significant increase in the number of claims or an increase\nin amounts owing under successful claims could materially adversely affect our business, financial condition, results of operations and\ncash flows."}